Medtronic (MDT) – Research Analysts’ Recent Ratings Changes

Medtronic (NYSE: MDT) has recently received a number of price target changes and ratings updates:

• 1/6/2026 – Medtronic was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
• 1/5/2026 – Medtronic had its “neutral” rating reaffirmed by analysts at Piper Sandler.
• 1/3/2026 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/29/2025 – Medtronic had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Medtronic was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/18/2025 – Medtronic had its price target lowered by analysts at Truist Financial Corporation from $110.00 to $107.00. They now have a “hold” rating on the stock.
• 12/16/2025 – Medtronic was given a new $103.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/2/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Medtronic had its price target raised by analysts at Daiwa Capital Markets from $104.00 to $117.00. They now have a “buy” rating on the stock.
• 11/22/2025 – Medtronic was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/20/2025 – Medtronic had its price target raised by analysts at Barclays PLC from $109.00 to $111.00. They now have an “overweight” rating on the stock.
• 11/20/2025 – Medtronic had its price target raised by analysts at Truist Financial Corporation from $103.00 to $110.00. They now have a “hold” rating on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at Sanford C. Bernstein.
• 11/19/2025 – Medtronic was given a new $120.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $110.00 price target on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic was upgraded by analysts at The Goldman Sachs Group, Inc. from a “sell” rating to a “neutral” rating. They now have a $111.00 price target on the stock, up previously from $81.00.
• 11/19/2025 – Medtronic had its price target raised by analysts at Morgan Stanley from $107.00 to $117.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Royal Bank Of Canada from $111.00 to $118.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at UBS Group AG from $95.00 to $102.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Wells Fargo & Company from $100.00 to $114.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Robert W. Baird from $103.00 to $109.00. They now have a “neutral” rating on the stock.
• 11/14/2025 – Medtronic had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 11/14/2025 – Medtronic had its “neutral” rating reaffirmed by analysts at Piper Sandler.
• 11/13/2025 – Medtronic had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $100.00. They now have a “neutral” rating on the stock.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).